Literature DB >> 10597306

Characterization of the chronic myelomonocytic leukemia associated TEL-PDGF beta R fusion protein.

T Sjöblom1, A Boureux, L Rönnstrand, C H Heldin, J Ghysdael, A Ostman.   

Abstract

The t(5;12) translocation, associated with chronic myelomonocytic leukemia, generates a novel gene encoding a protein, TEL-PDGF beta R, composed of the 154 amino-terminal amino acids of the transcription factor TEL and the transmembrane and intracellular part of the PDGF beta-receptor (PDGF beta R). TEL also occurs as a tumor-associated fusion partner for the tyrosine kinases c-ABL, JAK2 and TRK-C. Previous studies have demonstrated growth promoting activity of TEL-PDGF beta R and also indicated that the TEL moiety activates the tyrosine kinase of the PDGF beta R through the formation of TEL-PDGF beta R oligomers. We demonstrate that tyrosine phosphorylation of the fusion protein can be attenuated through overexpression of the TEL part of TEL-PDGF beta R, suggesting a strategy for antagonizing the signaling of TEL-PDGF beta R, and other TEL-fusion proteins containing tyrosine kinase domains. Comparison of BaF/3 cell lines expressing TEL-PDGF beta R and ligand-stimulated PDGF beta R revealed that only TEL-PDGF beta R expression conferred IL-3-independent growth, suggesting differences in signaling capacity of the two proteins. Finally, tyrosine residues 17 and 27 in TEL-PDGF beta R was identified as autophosphorylation sites in TEL-PDGF beta R.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10597306     DOI: 10.1038/sj.onc.1203190

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

1.  The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity.

Authors:  A Buijs; L van Rompaey; A C Molijn; J N Davis; A C Vertegaal; M D Potter; C Adams; S van Baal; E C Zwarthoff; M F Roussel; G C Grosveld
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.

Authors:  Alan Charest; Vicky Kheifets; Julie Park; Keara Lane; Kevin McMahon; Cathy L Nutt; David Housman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

Review 3.  Targeting non-malignant disorders with tyrosine kinase inhibitors.

Authors:  Friedrich Grimminger; Ralph T Schermuly; Hossein A Ghofrani
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

4.  Critical role of the platelet-derived growth factor receptor (PDGFR) beta transmembrane domain in the TEL-PDGFRbeta cytosolic oncoprotein.

Authors:  Federica Toffalini; Carina Hellberg; Jean-Baptiste Demoulin
Journal:  J Biol Chem       Date:  2010-02-17       Impact factor: 5.157

5.  Mutations in the SAM domain of the ETV6-NTRK3 chimeric tyrosine kinase block polymerization and transformation activity.

Authors:  Cristina E Tognon; Cameron D Mackereth; Aruna M Somasiri; Lawrence P McIntosh; Poul H B Sorensen
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

6.  Involvement of CD9 and PDGFR in migration is evolutionarily conserved from Drosophila glia to human glioma.

Authors:  Astrid Jeibmann; Kathrin Halama; Hanna Theresa Witte; Su Na Kim; Kristin Eikmeier; Björn Koos; Christian Klämbt; Werner Paulus
Journal:  J Neurooncol       Date:  2015-07-30       Impact factor: 4.130

7.  The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation.

Authors:  Federica Toffalini; Anders Kallin; Peter Vandenberghe; Pascal Pierre; Lucienne Michaux; Jan Cools; Jean-Baptiste Demoulin
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

Review 8.  Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.

Authors:  Sandrine Medves; Jean-Baptiste Demoulin
Journal:  J Cell Mol Med       Date:  2012-02       Impact factor: 5.310

9.  Identifying the Potential Role and Prognostic Value of the Platelet-Derived Growth Factor Pathway in Kidney Renal Clear Cell Carcinoma.

Authors:  Shiyong Xin; Xianchao Sun; Liang Jin; Zhen Zhou; Xiang Liu; Weiyi Li; Wangli Mei; Jiaxin Zhang; Bihui Zhang; Xudong Yao; Liqing Zhou; Lin Ye
Journal:  J Oncol       Date:  2022-03-17       Impact factor: 4.375

10.  The oncogenic FIP1L1-PDGFRα fusion protein displays skewed signaling properties compared to its wild-type PDGFRα counterpart.

Authors:  Serge Haan; Christelle Bahlawane; Jiali Wang; Petr V Nazarov; Arnaud Muller; René Eulenfeld; Claude Haan; Catherine Rolvering; Laurent Vallar; Venkata P Satagopam; Thomas Sauter; Monique Yvonne Wiesinger
Journal:  JAKSTAT       Date:  2015-07-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.